

References

- Amorin, B., Alegretti, A. P., Valim, V., Pezzi, A., Laureano, A. M., da Silva, M. A. L., Wieck, A., & Silla, L. (2014). Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. *Human Cell*, 27(4), 137–150. <https://doi.org/10.1007/s13577-014-0095-x>
- Ayala-Cuellar, A. P., Kang, J.-H., Jeung, E.-B., & Choi, K.-C. (2019). Roles of Mesenchymal Stem Cells in Tissue Regeneration and Immunomodulation. *Biomolecules & Therapeutics*, 27(1), 25–33. <https://doi.org/10.4062/biomolther.2017.260>
- Baur, R., Karl, F., Böttcher-Loschinski, R., Stoll, A., Völkl, S., Gießl, A., Flamann, C., Bruns, H., Schlötzer-Schrehardt, U., Böttcher, M., Schewe, D. M., Fischer, T., Jitschin, R., Mackensen, A., & Mougiakakos, D. (2023). Accumulation of T-cell-suppressive PD-L1^{high} extracellular vesicles is associated with GvHD and might impact GvL efficacy. *Journal for ImmunoTherapy of Cancer*, 11(3), e006362. <https://doi.org/10.1136/jitc-2022-006362>
- Bayati, F., Valadi, M., Ahmadi, A., Najafi, F., Bitar Ansaripour, & Ehsan Sharif-Paghaleh. (2022). Evaluation of immunomodulatory effects of co-culture or supernatant of dexamethasone or IFN- γ -treated adipose-derived mesenchymal stem cells on spleen mononuclear cells. *European Cytokine Network*, 33(3), 70–78. <https://doi.org/10.1684/ecn.2022.0482>
- Berumen Sánchez, G., Bunn, K. E., Pua, H. H., & Rafat, M. (2021). Extracellular vesicles: mediators of intercellular communication in tissue injury and disease. *Cell Communication and Signaling*, 19(1). <https://doi.org/10.1186/s12964-021-00787-y>
- Boland, L. K., Burand, A. J., Brown, A., Boyt, D. T., Lira, V. A., & Ankrum, J. A. (2017). IFN- γ and TNF- α Pre-licensing Protects Mesenchymal Stromal Cells from the Pro-inflammatory Effects of Palmitate. 26(3), 860–873. <https://doi.org/10.1016/j.ymthe.2017.12.013>
- Brignall, R., Cauchy, P., Bevington, S. L., Gorman, B., Pisco, A. O., Bagnall, J., Boddington, C., Rowe, W., England, H., Rich, K., Schmidt, L., Dyer, N. P., Travis, M. A., Ott, S., Jackson, D. A., Cockerill, P. N., & Paszek, P. (2017). Integration of Kinase and Calcium Signaling at the Level of Chromatin

- Underlies Inducible Gene Activation in T Cells. *The Journal of Immunology*, 199(8), 2652–2667. <https://doi.org/10.4049/jimmunol.1602033>
- Bulliard, Y., Freeborn, R., Uyeda, M. J., Humes, D., Bjordahl, R., de Vries, D., & Roncarolo, M. G. (2024). From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases. *Frontiers in Immunology*, 15, 1509956. <https://doi.org/10.3389/fimmu.2024.1509956>
- Burand, A. J., Di, L., Boland, L. K., Boyt, D. T., Schrodtt, M. V., Santillan, D. A., & Ankrum, J. A. (2020). Aggregation of Human Mesenchymal Stromal Cells Eliminates Their Ability to Suppress Human T Cells. *Frontiers in Immunology*, 11. <https://doi.org/10.3389/fimmu.2020.00143>
- Cai, Y., Ma, S., Liu, Y., Gong, H., Cheng, Q., Hu, B., Wu, Y., Yu, X., Dong, C., Sun, K., Wu, D., & Liu, H. (2016). Adoptively transferred donor IL-17-producing CD4⁺ T cells augment, but IL-17 alleviates, acute graft-versus-host disease. *Cellular & Molecular Immunology*, 15(3), 233–245. <https://doi.org/10.1038/cmi.2016.37>
- Caplan, A. I. (1991). Mesenchymal stem cells. *Journal of Orthopaedic Research*, 9(5), 641–650. <https://doi.org/10.1002/jor.1100090504>
- Choi, S. W., Levine, J. E., & Ferrara, J. L. M. (2014). Pathogenesis and Management of Graft-versus-Host Disease. *Immunology and Allergy Clinics of North America*, 30(1), 75–101. <https://doi.org/10.1016/j.iac.2009.10.001>
- Chopp, L. B., Redmond, C., O’Shea, J. J., & Schwartz, D. M. (2023). From thymus to tissues and tumors: A review of T-cell biology. *The Journal of Allergy and Clinical Immunology*, 151(1), 81–97. <https://doi.org/10.1016/j.jaci.2022.10.011>
- Cruz, F. F., Lins, L., & Rieken, P. (2018). Preparation of Extracellular Vesicles from Mesenchymal Stem Cells. *Stem Cells in Clinical Applications*, 37–51. https://doi.org/10.1007/978-3-319-99328-7_3

- Davies, L. C., Heldring, N., Kadri, N., & Le Blanc, K. (2016). Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. *STEM CELLS*, 35(3), 766–776. <https://doi.org/10.1002/stem.2509>
- Débora Moitinho Abram, Gustavo, L., Celso, A., & Patrícia Ucelli Simioni. (2017). The modulation of enzyme indoleamine 2,3-dioxygenase from dendritic cells for the treatment of type 1 diabetes mellitus. *Drug Design Development and Therapy*, Volume 11, 2171–2178. <https://doi.org/10.2147/dddt.s135367>
- del Rivero, T., Milberg, J., Bennett, C., Mitrani, M. I., & Bellio, M. A. (2022). Human amniotic fluid derived extracellular vesicles attenuate T cell immune response. *Frontiers in Immunology*, 13. <https://doi.org/10.3389/fimmu.2022.977809>
- Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*, 8(4), 315–317. <https://doi.org/10.1080/14653240600855905>
- Dörnen, J., & Dittmar, T. (2021). The Role of MSCs and Cell Fusion in Tissue Regeneration. *International Journal of Molecular Sciences*, 22(20), 10980. <https://doi.org/10.3390/ijms222010980>
- Doshi, A., Erickson, P., Teryek, M., & Parekkadan, B. (2023). Dynamics of Ex Vivo Mesenchymal Stromal Cell Potency under Continuous Perfusion. *International Journal of Molecular Sciences*, 24(11), 9602. <https://doi.org/10.3390/ijms24119602>
- Drobiova, H., Sindhu, S., Fahd Al-Mulla, Haddad, D., Abu-Farha, M., & Ashraf Al Madhoun. (2023). Wharton's jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications. *Frontiers in Cell and Developmental Biology*, 11. <https://doi.org/10.3389/fcell.2023.1211217>

- Friedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970). THE DEVELOPMENT OF FIBROBLAST COLONIES IN MONOLAYER CULTURES OF GUINEA-PIG BONE MARROW AND SPLEEN CELLS. *Cell Proliferation*, 3(4), 393–403. <https://doi.org/10.1111/j.1365-2184.1970.tb00347.x>
- Fu, Y., Sui, B., Xiang, L., Yan, X., Wu, D., Shi, S., & Hu, X. (2021). Emerging understanding of apoptosis in mediating mesenchymal stem cell therapy. *Cell Death & Disease*, 12(6). <https://doi.org/10.1038/s41419-021-03883-6>
- Fujii, S., & Miura, Y. (2022). Immunomodulatory and Regenerative Effects of MSC-Derived Extracellular Vesicles to Treat Acute GVHD. *Stem Cells*, 40(11), 977–990. <https://doi.org/10.1093/stmcls/sxac057>
- Fujii, S., Miura, Y., Aya Fujishiro, Shindo, T., Shimazu, Y., Hirai, H., Tahara, H., Akifumi Takaori-Kondo, Tatsuo Ichinohe, & Maekawa, T. (2018). *Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations*. 36(3), 434–445. <https://doi.org/10.1002/stem.2759>
- Gupta, M., Tieu, A., Slobodian, M., Shorr, R., Burger, D., Lalu, M. M., & Allan, D. S. (2020). Preclinical Studies of MSC-Derived Extracellular Vesicles to Treat or Prevent Graft Versus Host Disease: a Systematic Review of the Literature. *Stem Cell Reviews and Reports*, 17(2), 332–340. <https://doi.org/10.1007/s12015-020-10058-x>
- Gürsoy, G., GÜRLEK GÖKÇEBAY, D., & ÖZBEK, N. Y. (2024). Mesenchymal Stem Cell Applications in Graft Versus Host Disease. *Turkish Journal of Pediatric Disease*, 1–8. <https://doi.org/10.12956/tchd.1415924>
- Haddad, R., & Saldanha-Araujo, F. (2014). Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far? *BioMed Research International*, 2014, 1–14. <https://doi.org/10.1155/2014/216806>
- Han, Y., Yang, J., Fang, J., Zhou, Y., Candi, E., Wang, J., Hua, D., Shao, C., & Shi, Y. (2022). The secretion profile of mesenchymal stem cells and potential applications in treating human diseases.

- Signal Transduction and Targeted Therapy*, 7(1), 1–19.
<https://doi.org/10.1038/s41392-022-00932-0>
- Hansen, S. B., Højgaard, L. D., Kastrup, J., Ekblond, A., Follin, B., & Juhl, M. (2022). Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell. *Frontiers in Immunology*, 13. <https://doi.org/10.3389/fimmu.2022.1085312>
- Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019). Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. *Cells*, 8(12), 1605. <https://doi.org/10.3390/cells8121605>
- Huang, Y., Wu, Q., & Tam, P. K. H. (2022). Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications. *International Journal of Molecular Sciences*, 23(17), 10023. <https://doi.org/10.3390/ijms231710023>
- Huldani, H., Rashid, A. I., Turaev, K. N., Oplencia, M. J. C., Abdelbasset, W. K., Bokov, D. O., Mustafa, Y. F., Al-Gazally, M. E., Hammid, A. T., Kadhim, M. M., & Ahmadi, S. H. (2022). Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential. *Cell Communication and Signaling*, 20(1).
<https://doi.org/10.1186/s12964-022-00972-7>
- Ji, T., & Li, H. (2023). T-helper cells and their cytokines in pathogenesis and treatment of asthma. *Frontiers in Immunology*, 14. <https://doi.org/10.3389/fimmu.2023.1149203>
- Jiang, W., & Xu, J. (2019). Immune modulation by mesenchymal stem cells. *Cell Proliferation*, 53(1).
<https://doi.org/10.1111/cpr.12712>
- Jiang, Y., Zhao, J., Wang, M., Huang, F., Li, J., Liu, R., Wan, J., & Hao, S. (2023). Mesenchymal stem cell-derived exosomes can alleviate GVHD and preserve the GVL effect in allogeneic stem cell transplantation animal models. *Frontiers in Immunology*, 14.
<https://doi.org/10.3389/fimmu.2023.1284936>

- Joaquín Cagliani, Grande, D., Molmenti Ep, Miller, E. S., & Rilo Hlr. (2017). Immunomodulation by Mesenchymal Stromal Cells and Their Clinical Applications. *Journal of Stem Cell and Regenerative Biology*, 3(2), 1–14. <https://doi.org/10.15436/2471-0598.17.022>
- Jovic, D., Yu, Y., Wang, D., Wang, K., Li, H., Xu, F., Liu, C., Liu, J., & Luo, Y. (2022). A Brief Overview of Global Trends in MSC-Based Cell Therapy. *Stem Cell Reviews and Reports*, 18(5), 1525–1545. <https://doi.org/10.1007/s12015-022-10369-1>
- Justiz Vaillant, A. A., & Mohammadi, O. (2020). *Graft Versus Host Disease*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK538235/>
- Kadri, N., Amu, S., Iacobaeus, E., Boberg, E., & Le Blanc, K. (2023). Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. *Cellular & Molecular Immunology*, 20(6), 613–625. <https://doi.org/10.1038/s41423-023-01022-z>
- Kelly, K., & Rasko, J. E. J. (2021). Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. *Frontiers in Immunology*, 12. <https://doi.org/10.3389/fimmu.2021.761616>
- Kim, K.-H., Kim, S.-H., Jung, H.-H., Moon, J.-H., Jeong, S.-U., Yu, K., & Lee, C.-K. (2018). Thapsigargin Increases IL-2 Production in T Cells at Nanomolar Concentrations. *Immune Network*, 18(4), e26. <https://doi.org/10.4110/in.2018.18.e26>
- Kim, Y., Hye Jin Jin, Heo, J., Ju, H., Lee, H.-Y., Kim, S., Lee, S., Lim, J., Sang Young Jeong, Kwon, J., Kim, M., Soo Jin Choi, Oh, W., Yoon Sun Yang, Hyun Ho Hwang, Hwan Yeul Yu, Ryu, C.-M., Hong Bae Jeon, & Shin, D.-M. (2018). Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease. *Leukemia*, 32(12), 2672–2684. <https://doi.org/10.1038/s41375-018-0151-8>
- Klein Geltink, R. I., Kyle, R. L., & Pearce, E. L. (2018). Unraveling the Complex Interplay Between T Cell Metabolism and Function. *Annual Review of Immunology*, 36(1), 461–488. <https://doi.org/10.1146/annurev-immunol-042617-053019>
- Laranjeira, P., Pedrosa, M., Pedreiro, S., Gomes, J., Martinho, A., Antunes, B., Ribeiro, T., Santos, F., Trindade, H., & Paiva, A. (2015). Effect of human bone marrow mesenchymal stromal cells on

- cytokine production by peripheral blood naive, memory, and effector T cells. *Stem Cell Research & Therapy*, 6(1), 3. <https://doi.org/10.1186/scrt537>
- Laura Marie Gail, Kimberly Julia Schell, Piotr Łacina, Strobl, J., Bolton, S. J., Emilie Steinbakk Ulriksen, Katarzyna Bogunia-Kubik, Greinix, H., Rachel Emily Crossland, Marit Inngjerdigen, & Stry, G. (2023). Complex interactions of cellular players in chronic Graft-versus-Host Disease. *Frontiers in Immunology*, 14. <https://doi.org/10.3389/fimmu.2023.1199422>
- Li, Y., Hao, J., Hu, Z., Yang, Y.-G., Zhou, Q., Sun, L., & Wu, J. (2022). Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. *Stem Cell Research & Therapy*, 13(1). <https://doi.org/10.1186/s13287-022-02751-0>
- Lia, G., Di Vito, C., Cerrano, M., Brunello, L., Calcaterra, F., Tapparo, M., Giaccone, L., Mavilio, D., & Bruno, B. (2020). Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications. *Frontiers in Immunology*, 11. <https://doi.org/10.3389/fimmu.2020.00422>
- Liu, Y.-J., & Wang, C. (2023). A review of the regulatory mechanisms of extracellular vesicles-mediated intercellular communication. *Cell Communication and Signaling*, 21(1). <https://doi.org/10.1186/s12964-023-01103-6>
- López-García, L., & Castro-Manrreza, M. E. (2021). TNF- α and IFN- γ Participate in Improving the Immunoregulatory Capacity of Mesenchymal Stem/Stromal Cells: Importance of Cell–Cell Contact and Extracellular Vesicles. *International Journal of Molecular Sciences*, 22(17), 9531. <https://doi.org/10.3390/ijms22179531>
- Luk, A. O. Y., Ng, S. S. S., & Holt, R. I. G. (2021). Impact of diabetes on COVID-19 and other infection: Report from the 22nd Hong Kong Diabetes and Cardiovascular Risk Factors—East Meets West Symposium. *Diabetic Medicine*, 38(5). <https://doi.org/10.1111/dme.14547>
- M Nguyen, T., & Arthur, A. (2016). Eph/Ephrin-mediated Mesenchymal Stem Cell Regulation of T-cell Activation and Function. *Journal of Clinical & Cellular Immunology*, 7(3). <https://doi.org/10.4172/2155-9899.1000418>

- Ma, O. K.-F., & Chan, K. H. (2016). Immunomodulation by mesenchymal stem cells: Interplay between mesenchymal stem cells and regulatory lymphocytes. *World Journal of Stem Cells*, 8(9), 268. <https://doi.org/10.4252/wjsc.v8.i9.268>
- Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023). Acute graft-versus-host disease. *Nature Reviews. Disease Primers*, 9(1), 27. <https://doi.org/10.1038/s41572-023-00438-1>
- Malard, F., Huang, X.-J., & Sim, J. P. Y. (2020). Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. *Leukemia*, 34(5), 1229–1240. <https://doi.org/10.1038/s41375-020-0804-2>
- Marinescu, C.-I., Preda, M. B., & Burlacu, A. (2021). A procedure for in vitro evaluation of the immunosuppressive effect of mouse mesenchymal stem cells on activated T cell proliferation. *Stem Cell Research & Therapy*, 12(1). <https://doi.org/10.1186/s13287-021-02344-3>
- Mázló, A., Kovács, R., Miltner, N., Tóth, M., Veréb, Z., Szabó, K., Bacskai, I., Pázmándi, K., Apáti, Á., Bíró, T., Bene, K., Rajnavölgyi, É., & Bácsi, A. (2021). MSC-like cells increase ability of monocyte-derived dendritic cells to polarize IL-17-/IL-10-producing T cells via CTLA-4. *iScience*, 24(4), 102312. <https://doi.org/10.1016/j.isci.2021.102312>
- Merimi, M., El-Majzoub, R., Lagneaux, L., Moussa Agha, D., Bouhtit, F., Meuleman, N., Fahmi, H., Lewalle, P., Fayyad-Kazan, M., & Najjar, M. (2021). The Therapeutic Potential of Mesenchymal Stromal Cells for Regenerative Medicine: Current Knowledge and Future Understandings. *Frontiers in Cell and Developmental Biology*, 9. <https://doi.org/10.3389/fcell.2021.661532>
- Morata-Tarifa, C., Macías-Sánchez, M. D. M., Gutiérrez-Pizarra, A., & Sanchez-Pernaute, R. (2020). Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. *Stem Cell Research & Therapy*, 11(1), 64. <https://doi.org/10.1186/s13287-020-01592-z>

- Mousa Mohammadnia-Afrouzi, Shahbazi, M., Sedigheh Baleghi Damavandi, Ganji, G. F., & Soheil Ebrahimpour. (2017). Regulatory T-cell: Regulator of Host Defense in Infection. *Journal of Molecular Biology Research*, 7(1), 9–9. <https://doi.org/10.5539/jmbr.v7n1p9>
- Murray, J., Stringer, J., & Hutt, D. (2023). Graft-Versus-Host Disease (GvHD). *Springer EBooks*, 241–267. https://doi.org/10.1007/978-3-031-23394-4_12
- Naserian, S., Leclerc, M., Shamdani, S., & Uzan, G. (2020). Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies. *Frontiers in Immunology*, 11. <https://doi.org/10.3389/fimmu.2020.607030>
- Nastaran Azarbarz, Fatemeh Rezaei-Tazangi, Zeinab Shafiei Seifabadi, & Nejad, D. B. (2024). Therapeutic Effects of Wharton’s Jelly Mesenchymal Stem Cells: from Laboratory to Clinical Application. *Brazilian Archives of Biology and Technology*, 67. <https://doi.org/10.1590/1678-4324-2024220300>
- Negi, N., & Griffin, M. D. (2020). Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. *STEM CELLS*, 38(5), 596–605. <https://doi.org/10.1002/stem.3151>
- Paliwal, S., Chaudhuri, R., Agrawal, A., & Mohanty, S. (2018). Regenerative abilities of mesenchymal stem cells through mitochondrial transfer. *Journal of Biomedical Science*, 25(1). <https://doi.org/10.1186/s12929-018-0429-1>
- Pang, S. H. M., D’Rozario, J., Mendonca, S., Bhuvan, T., Payne, N. L., Zheng, D., Hisana, A., Wallis, G., Barugahare, A., Powell, D., Rautela, J., Huntington, N. D., Dewson, G., Huang, D. C. S., Gray, D. H. D., & Heng, T. S. P. (2021). Mesenchymal stromal cell apoptosis is required for their therapeutic function. *Nature Communications*, 12(1). <https://doi.org/10.1038/s41467-021-26834-3>
- Park, K.-S., Bandeira, E., Shelke, G. V., Lässer, C., & Lötval, J. (2019). Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. *Stem Cell Research & Therapy*, 10(1). <https://doi.org/10.1186/s13287-019-1398-3>

- Qi, J., Tang, X., Li, W., Chen, W., Yao, G., & Sun, L. (2020). Mesenchymal stem cells inhibited the differentiation of MDSCs via COX2/PGE2 in experimental sialadenitis. *Stem Cell Research & Therapy*, 11(1). <https://doi.org/10.1186/s13287-020-01837-x>
- Qi, K., Li, N., Zhang, Z., & Melino, G. (2018). Tissue regeneration: The crosstalk between mesenchymal stem cells and immune response. *Cellular Immunology*, 326, 86–93. <https://doi.org/10.1016/j.cellimm.2017.11.010>
- Reza Rezaee, Verdi, J., Sadeghi, M., Mehran Soleymanha, Mojtaba Mirzaei, Mobayen, M. R., & Arad Kianoush. (2022). The application of human Wharton's jelly mesenchymal stem cells in wound healing: A narrative review. *Journal of Current Biomedical Reports*, 3(1), 1–13. <https://doi.org/10.52547/jcbior.3.1.1>
- Saeedi, P., Halabian, R., & Imani Fooladi, A. A. (2019). A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. *Stem Cell Investigation*, 6(34), 34–34. <https://doi.org/10.21037/sci.2019.08.11>
- Sagaradze, G. D., Basalova, N. A., Efimenko, A. Yu., & Tkachuk, V. A. (2020). Mesenchymal Stromal Cells as Critical Contributors to Tissue Regeneration. *Frontiers in Cell and Developmental Biology*, 8. <https://doi.org/10.3389/fcell.2020.576176>
- Saleh, M., Vaezi, A. A., Aliannejad, R., Sohrabpour, A. A., Kiaei, S. Z. F., Shadnoush, M., Siavashi, V., Aghaghazvini, L., Khoundabi, B., Abdoli, S., Chahardouli, B., Seyhoun, I., Alijani, N., & Verdi, J. (2021). Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial. *Stem Cell Research & Therapy*, 12(1). <https://doi.org/10.1186/s13287-021-02483-7>
- Sanaz Keshavarz Shahbaz, Amirhossein Mansourabadi, & Jafari, D. (2022). Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease. *Clinical and Experimental Immunology*, 208(1), 12–24. <https://doi.org/10.1093/cei/uxac016>

- Saparov, A., Ogay, V., Nurgozhin, T., Jumabay, M., & Chen, W. C. W. (2016). Preconditioning of Human Mesenchymal Stem Cells to Enhance Their Regulation of the Immune Response. *Stem Cells International*, 2016, 1–10. <https://doi.org/10.1155/2016/3924858>
- Shen, M.-Z., Liu, X.-X., Qiu, Z.-Y., Xu, L.-P., Zhang, X.-H., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., Liu, S.-N., Liu, K.-Y., Huang, X.-J., & Mo, X.-D. (2022). Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation. *Therapeutic Advances in Hematology*, 13, 204062072110728-204062072110728. <https://doi.org/10.1177/20406207211072838>
- Shinohara, Y., & Tsukimoto, M. (2018). Adenine Nucleotides Attenuate Murine T Cell Activation Induced by Concanavalin A or T Cell Receptor Stimulation. *Frontiers in Pharmacology*, 8. <https://doi.org/10.3389/fphar.2017.00986>
- Shrihari, S., Foppiani, E., Goss, K., Gafford, G., Daley-Bauer, L., & Horwitz, E. (2023). IFN γ Primed MSCs Suppress Stimulated T Cells By Inducing Perturbations of Redox Homeostasis. *Blood*, 142(Supplement 1), 4799–4799. <https://doi.org/10.1182/blood-2023-190124>
- Silva-Carvalho, A. É., Rodrigues, L. P., Schiavinato, J. L., Alborghetti, M. R., Bettarello, G., Simões, B. P., Neves, F. de A. R., Panepucci, R. A., de Carvalho, J. L., & Saldanha-Araujo, F. (2020). GVHD-derived plasma as a priming strategy of mesenchymal stem cells. *Stem Cell Research & Therapy*, 11(1). <https://doi.org/10.1186/s13287-020-01659-x>
- Song, N., Scholtemeijer, M., & Shah, K. (2020). Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. *Trends in Pharmacological Sciences*, 41(9), 653–664. <https://doi.org/10.1016/j.tips.2020.06.009>
- Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023). T cells in health and disease. *Signal Transduction and Targeted Therapy*, 8(1). <https://doi.org/10.1038/s41392-023-01471-y>
- Sun, S.-C. (2017). The non-canonical NF- κ B pathway in immunity and inflammation. *Nature Reviews Immunology*, 17(9), 545–558. <https://doi.org/10.1038/nri.2017.52>

- Tago, Y., Kobayashi, C., Ogura, M., Wada, J., Yamaguchi, S., Yamaguchi, T., Hayashi, M., Nakaishi, T., Kubo, H., & Ueda, Y. (2021). Human amnion-derived mesenchymal stem cells attenuate xenogeneic graft-versus-host disease by preventing T cell activation and proliferation. *Scientific Reports*, 11(1). <https://doi.org/10.1038/s41598-021-81916-y>
- Tik Shing Cheung, Giacomini, C., Matteo Cereda, Avivar-Valderas, A., Capece, D., Giuliana Minani Bertolino, None Olga delaRosa, Hicks, R., Ciccocioppo, R., Franzoso, G., Galleu, A., Ciccarelli, F. D., & Dazzi, F. (2023). Apoptosis in mesenchymal stromal cells activates an immunosuppressive secretome predicting clinical response in Crohn's disease. *Molecular Therapy*, 31(12), 3531–3544. <https://doi.org/10.1016/j.ymthe.2023.10.004>
- Trickett, A., & Kwan, Y. L. (2003). T cell stimulation and expansion using anti-CD3/CD28 beads. *Journal of Immunological Methods*, 275(1-2), 251–255. [https://doi.org/10.1016/s0022-1759\(03\)00010-3](https://doi.org/10.1016/s0022-1759(03)00010-3)
- van Baren, N., & Van den Eynde, B. J. (2015). Tryptophan-Degrading Enzymes in Tumoral Immune Resistance. *Frontiers in Immunology*, 6. <https://doi.org/10.3389/fimmu.2015.00034>
- Vieira Paladino, F., de Moraes Rodrigues, J., da Silva, A., & Goldberg, A. C. (2019). The Immunomodulatory Potential of Wharton's Jelly Mesenchymal Stem/Stromal Cells. *Stem Cells International*, 2019, 1–7. <https://doi.org/10.1155/2019/3548917>
- Voisin, C., Cauchois, G., Reppel, L., Laroye, C., Laetitia Louarn, Schenowitz, C., Sonon, P., Poras, I., Wang, V., Carosella, E. D., Benkirane-Jessel, N., Moreau, P., Rouas-Freiss, N., Danièle Bensoussan, & Céline Huselstein. (2020). Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation? *Journal of Clinical Medicine*, 9(2), 423–423. <https://doi.org/10.3390/jcm9020423>
- Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020). A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nature Reviews Immunology*, 20(20), 1–18. <https://doi.org/10.1038/s41577-020-0306-5>

- Wang, F., Liu, L., Wang, J., Liu, M., Zhang, W., Zhao, L., Zhai, C., & Xu, Y. (2023). Gain-of-function of IDO in DCs inhibits T cell immunity by metabolically regulating surface molecules and cytokines. *Experimental and Therapeutic Medicine*, 25(5). <https://doi.org/10.3892/etm.2023.11933>
- Wang, M., Yuan, Q., & Xie, L. (2018). Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application. *Stem Cells International*, 2018, 1–12. <https://doi.org/10.1155/2018/3057624>
- Weiss, A. R. R., & Dahlke, M. H. (2019). Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. *Frontiers in Immunology*, 10. <https://doi.org/10.3389/fimmu.2019.01191>
- Wu, A. A., Drake, V., Huang, H.-S., Chiu, S., & Zheng, L. (2015). Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. *Oncot Immunology*, 4(7), e1016700. <https://doi.org/10.1080/2162402x.2015.1016700>
- Xin Ya Loke, Imran, M., Gee Jun Tye, Safwani, W., & Nordin, F. (2021). Immunomodulation and Regenerative Capacity of MSCs for Long-COVID. *International Journal of Molecular Sciences*, 22(22), 12421–12421. <https://doi.org/10.3390/ijms222212421>
- Yan, L., Li, J., & Zhang, C. (2023). The role of MSCs and CAR-MSCs in cellular immunotherapy. *Cell Communication and Signaling*, 21(1). <https://doi.org/10.1186/s12964-023-01191-4>
- Yubo, M., Yanyan, L., Li, L., Tao, S., Bo, L., & Lin, C. (2017). Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: A meta-analysis. *PLOS ONE*, 12(4), e0175449. <https://doi.org/10.1371/journal.pone.0175449>
- Yulia Suzdaltseva, Kirill Goryunov, Ekaterina Silina, Manturova, N., Stupin, V., & Kiselev, S. L. (2022). Equilibrium among Inflammatory Factors Determines Human MSC-Mediated Immunosuppressive Effect. *Cells*, 11(7), 1210–1210. <https://doi.org/10.3390/cells11071210>
- Zhao, K., Ruan, S., Yin, L., Zhao, D., Chen, C., Pan, B., Zeng, L., Li, Z., & Xu, K. (2016). Dynamic regulation of effector IFN- γ -producing and IL-17-producing T cell subsets in the development

- of acute graft-versus-host disease. *Molecular Medicine Reports*, 13(2), 1395–1403.
<https://doi.org/10.3892/mmr.2015.4638>
- Zhao, L., Chen, S., Yang, P., Cao, H., & Li, L. (2019). The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. *Stem Cell Research & Therapy*, 10(1). <https://doi.org/10.1186/s13287-019-1287-9>
- Zheng, S., Huang, K., Xia, W., Shi, J., Liu, Q., Zhang, X., Li, G., Chen, J., Wang, T., Chen, X., & Andy Peng Xiang. (2021). Mesenchymal Stromal Cells Rapidly Suppress TCR Signaling-Mediated Cytokine Transcription in Activated T Cells Through the ICAM-1/CD43 Interaction. *Frontiers in Immunology*, 12. <https://doi.org/10.3389/fimmu.2021.609544>
- Zhou, X., Jin, N., Wang, F., & Chen, B. (2020). Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease. *Cancer Cell International*, 20(1).
<https://doi.org/10.1186/s12935-020-01193-z>